United Kingdom

Respiratory

Our range of respiratory medicines means we share a common interest with respiratory specialists.


We focus on supporting the NHS and the Department of Health in managing long-term conditions like asthma and chronic obstructive pulmonary disease (COPD). We address cost-efficient prescribing and develop joined-up care through our Joint Working projects to help improve patient outcomes and also offer value for money. 

By recognising aligned goals and objectives in areas of mutual interest, we can work jointly to improve patient outcomes and enhance patient experience. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies. 

Respiratory conditions account for a significant portion of the NHS budget and resources
__________________________________________________________________________________________________________________

Over five million people in the UK are currently receiving treatment for asthma and the NHS is thought to spend over £1 billion each year treating the condition.1

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in the UK. It is estimated that 3 million people have COPD, of whom 2 million are undiagnosed,2 often because people are reluctant to seek medical help, and perhaps ignore their symptoms.

Around 10,000 people are also living with Cystic Fibrosis, it is one of the UK’s most common life-shortening inherited conditions, affecting around one in 2,500 live births.3

"As well as developing and providing our own specialty medicines dedicated to the treatment of asthma, COPD and Cystic Fibrosis, we provide a range of information, consultation and education services to help you manage and improve the service you provide to your patients. This includes inhaler technique training and helping patients understand how compliance and self management of their condition can benefit their overall health."

DuoResp Spiromax® (budesonide formoterol)

DuoResp Spiromax

DuoResp Spiromax® is a multi-dose dry-powder inhaler that contains a fixed dose combination of budesonide and formoterol fumarate dehydrate.

DuoResp Spiromax is indicated in adults 18 years of age and older for:

  1. The regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists or in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.4
  2. The symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.4

The budesonide is an inhaled corticosteroid which treats the underlying inflammation in asthma and COPD. The formoterol fumarate dihydrate is a rapid-acting and long-lasting β2 agonist for the relief of bronchoconstriction.4

Both of these ingredients are important in achieving good asthma and COPD control. However, a substantial percentage of inhaler users worldwide have inadequate inhaler technique and increased inhalation errors, resulting in poor drug delivery to the lungs.5

"The Spiromax® device is designed to be uncomplicated and user-friendly so adult patients can use it well and their medicine can get to work where it is needed."

DuoResp Spiromax® 160mcg/4.5mcg also has a maintenance and reliever therapy (MART) license.4  

DuoResp Spiromax® 160mcg/4.5mcg dry powder inhaler 

Each delivered dose (the dose that leaves the mouthpiece of the Spiromax®) contains 160mcg of budesonide and 4.5mcg of formoterol fumarate dihydrate. This is equivalent to a metered dose of 200mcg budesonide and 6mcg of formoterol fumarate dihydrate.4

DuoResp Spiromax® 320mcg/9mcg dry powder inhaler 

Each delivered dose (the dose that leaves the mouthpiece of the Spiromax®) contains 320mcg of budesonide and 9mcg of formoterol fumarate dihydrate. This is equivalent to a metered dose of 400mcg budesonide and 12mcg of formoterol fumarate dihydrate.4

Abbreviated Prescribing Information - DuoResp Spiromax® >

More about DuoResp Spiromax >

Marketing authorisation: 

Teva Pharma B.V.

Swensweg 5, 2031GA Haarlem

The Netherlands 

EU/1/14/920/001-006

Braltus Zonda® (tiotropium)

Braltus ZondaBraltus Zonda® (tiotropium) is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). Braltus is indicated for use in adults.6

Zonda® is a breath-actuated inhaler.

Abbreviated Prescribing Information - Braltus® (tiotropium bromide) Inhalation Powder >

More about Braltus Zonda > 

Marketing authorisation:  

Teva UK Limited
Brampton Road, 
Hampden Park, Eastbourne, BN22 9AG
United Kingdom 

PL 00289/1870 

Qvar® (CFC free beclometasone dipropionate)

QvarFor asthma, Teva provides the Qvar® (CFC free beclometasone dipropionate) range of products, including Qvar® Easi-Breathe® (CFC free beclometasone dipropionate), a breath-actuated inhaler. Qvar® is also available in Autohaler® and metered dose inhaler for the prophylactic management of mild, moderate or severe asthma.7

CINQAERO®(reslizumab)

CINQAERO®▼ (reslizumab) is a solution for infusion as an add-on therapy for adult severe eosinophilic asthma.8

CINQAERO

 

For prescribing information click here >

Marketing Authorisation Holder: 

Teva B.V., Swensweg 5, 2031 GA Haarlem, Netherlands

EU/1/16/1125/001-2

Tymbrineb® (tobramycin)

TymbrinebTymbrineb® (tobramycin) 300 mg/5 ml Nebuliser Solution is used for the long-term management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged six years and older with Cystic Fibrosis.

Tymbrineb® Nebuliser Solution is indicated in adults, adolescents and children aged six years and older.9


Support for healthcare professionals
_____________________________________________________________________

  • For factual, scientific-based information about Teva's range of inhalers and treatments for respiratory conditions you can contact our Medical Information Service via email medinfo@tevauk.com or call 0207 540 7117
  • Further information on our products can be found on our product catologue
  • You can also request a visit from a Teva representative here

 

Teva's Respiratory Educational Programme
_____________________________________________________________________

 

Let’s Talk Respiratory is Teva’s supportive educational programme of materials, resources and some of the latest news in respiratory for HCPs.

Our updated site for healthcare professionals introduces a fresh design with a host of new functions and features to improve the customer’s experience, providing access to the latest information, education and insights. The aim of the platform is to support and encourage HCP’s, to help them empower their patients and to make a real difference to the lives of those living with respiratory conditions, primarily asthma and COPD.

Let's Talk Respiratory - Go to website >

 

Joint Working
_____________________________________________________________________

We work in partnership with multiple Clinical Commissioning Groups across the country to deliver improved patient outcomes. This is through such Joint Working projects as advanced inhaler training, improving patient education and clinical management of asthma and COPD as well as many more projects. Our Joint Working projects are available on our Joint Working pages.

To discuss potential Joint Working opportunities with Teva within respiratory you can contact us and a representative from Teva will be in touch.

 

___________________________________________________________________________________________________

References:

[1] http://www.asthma.org.uk/asthma-facts-and-statistics accessed 18.04.18

[2] https://www.nice.org.uk/guidance/qs10/chapter/introduction accessed 18.04.18

[3] https://www.cysticfibrosis.org.uk/what-is-cystic-fibrosis/faqs accessed 18.04.2018

[4] DuoResp Spiromax® 320 micrograms/9 micrograms and 160 micrograms/4.5 micrograms inhalation powder - Summary of Product Characteristics

[5] Price D et al. Resp Med, 2013; 107: 37–46.

[6] Braltus Zonda® (tiotropium) - Summary of Product Characteristics

[7] Qvar® (CFC free beclometasone dipropionate) - Summary of Product Characteristics

[8] Cinqaero® (reslizumab) - Summary of Product Characteristics

[9] Tymbrineb® (tobramycin) - Summary of Product Characteristics

Teva Ref: HC608